{
  "guideline" : {
    "objCls" : "Guideline",
    "@id" : "https://api.pharmgkb.org/data/guideline/PA166105003",
    "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
    "id" : "PA166105003",
    "name" : "CPIC Guideline for allopurinol and HLA-B",
    "descriptiveVideoId" : "qbDsCEYbo4k",
    "history" : [ {
      "id" : 1183699762,
      "date" : "2012-10-17T00:00:00-07:00",
      "type" : "create",
      "version" : 0
    }, {
      "id" : 1444841843,
      "date" : "2015-06-11T15:10:54.200-07:00",
      "description" : "Published update",
      "type" : "update",
      "version" : 0
    }, {
      "id" : 1444841850,
      "date" : "2015-06-12T08:50:16.155-07:00",
      "type" : "update",
      "version" : 0
    } ],
    "relatedChemicals" : [ {
      "objCls" : "Chemical",
      "@id" : "https://api.pharmgkb.org/data/chemical/PA448320",
      "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
      "id" : "PA448320",
      "name" : "allopurinol",
      "version" : 4
    } ],
    "relatedGenes" : [ {
      "objCls" : "Gene",
      "@id" : "https://api.pharmgkb.org/data/gene/PA35056",
      "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
      "id" : "PA35056",
      "symbol" : "HLA-B",
      "name" : "major histocompatibility complex, class I, B",
      "version" : 39
    } ],
    "source" : "CPIC",
    "summaryMarkdown" : {
      "id" : 1447981950,
      "externalLinks" : [ ],
      "html" : "<p>Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (&quot;HLA-B*58:01-positive&quot;) due to significantly increased risk of allopurinol-induced SCAR.</p>\n",
      "internalLinks" : [ ],
      "markdown" : "Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (\"HLA-B*58:01-positive\") due to significantly increased risk of allopurinol-induced SCAR.",
      "pmids" : [ ],
      "relatedObjects" : [ ],
      "version" : 0
    },
    "summaryVideoId" : "V8DGK_BaHHg",
    "terms" : [ {"@id":"https://api.pharmgkb.org/data/ontologyTerm/cpicStatus/cpicStatus:1183847844","@context":"https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld","id":1183847844,"resource":"CPIC Status","term":"A","termId":"cpicStatus:1183847844"} ],
    "textMarkdown" : {
      "id" : 1447981949,
      "externalLinks" : [ "https://cpicpgx.org", "https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2013/23232549-supplement.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2013/23232549.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2015/26094938-supplement.pdf", "https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2015/26094938.pdf" ],
      "html" : "<h3 id=\"january-2016\">January 2016</h3>\n<p><em>Accepted article preview online June 2015</em></p>\n<p>The 2015 update of CPIC guidelines regarding allopurinol has been published in <em>Clinical Pharmacology and Therapeutics</em>.  Recent literature was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>.</p>\n<ul>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fallopurinol%2F2015%2F26094938.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update </a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fallopurinol%2F2015%2F26094938-supplement.pdf\" target=\"_blank\">2015 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"february-2013\">February 2013</h3>\n<p><em>Advanced online publication December 2012</em></p>\n<ul>\n<li>Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the <a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fcpicpgx.org\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</li>\n<li>These guidelines are applicable to:\n<ul>\n<li>adults</li>\n</ul>\n</li>\n<li>Excerpt from the 2013 allopurinol dosing guidelines:\n<ul>\n<li>&quot;Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.&quot;</li>\n</ul>\n</li>\n<li>Download and read:\n<ul>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fallopurinol%2F2013%2F23232549.pdf\" target=\"_blank\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing </a></li>\n<li><a rel=\"noopener noreferrer\" href=\"https://api.pharmgkb.org/v1/site/redirect?p=https%3A%2F%2Fgithub.com%2FPharmGKB%2Fcpic-guidelines%2Fraw%2Fmaster%2Fallopurinol%2F2013%2F23232549-supplement.pdf\" target=\"_blank\">2013 supplement</a>.</li>\n</ul>\n</li>\n</ul>\n<h3 id=\"table-1-recommended-dosing-of-allopurinol-based-on-hla-b-genotype\">Table 1: Recommended dosing of allopurinol based on <em>HLA-B</em> genotype</h3>\n<table class=\"table\">\n<thead>\n<tr><th>Likely Phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for allopurinol therapy</th><th>Classification of recommendation for allopurinol therapy</th></tr>\n</thead>\n<tbody>\n<tr><td>Low or reduced risk of allopurinol SCAR</td><td>Absence of <em>*58:01</em> alleles (reported as &quot;negative&quot; on a genotyping test)</td><td>*X/*X <sup>a</sup></td><td>Low or reduced risk of allopurinol SCAR</td><td>Use allopurinol per standard dosing guidelines</td><td>Strong</td></tr>\n<tr><td>Significantly increased risk of allopurinol SCAR</td><td>Presence of at least one <em>*58:01</em> allele (reported as &quot;positive&quot; on a genotyping test)</td><td><em>*58:01</em>/*X <sup>a</sup> <em>*58:01/*58:01</em></td><td>Significantly increased risk of allopurinol SCAR</td><td>Allopurinol is contraindicated</td><td>Strong</td></tr>\n</tbody>\n</table>\n<p><em>Adapted from Table 2 of the 2013 Guideline Manuscript</em></p>\n<p><sup>a</sup> *X = any <em>HLA-B</em> genotype other than <em>*58:01</em>.</p>\n<p><em>HLA-B</em> = human leukocyte antigen B</p>\n",
      "internalLinks" : [ ],
      "markdown" : "## January 2016\r\n\r\n_Accepted article preview online June 2015_\r\n\r\nThe 2015 update of CPIC guidelines regarding allopurinol has been published in _Clinical Pharmacology and Therapeutics_.  Recent literature was reviewed and there is __no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current__. \r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update ](https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2015/26094938.pdf) \r\n  - [2015 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2015/26094938-supplement.pdf). \r\n\r\n## February 2013\r\n\r\n_Advanced online publication December 2012_\r\n- Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the [Clinical Pharmacogenetics Implementation Consortium (CPIC)](https://cpicpgx.org).\r\n- These guidelines are applicable to:\r\n  - adults\r\n- Excerpt from the 2013 allopurinol dosing guidelines:\r\n  - \"Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.\"\r\n- Download and read:\r\n  - [Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing ](https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2013/23232549.pdf) \r\n  - [2013 supplement](https://github.com/PharmGKB/cpic-guidelines/raw/master/allopurinol/2013/23232549-supplement.pdf). \r\n\r\n## Table 1: Recommended dosing of allopurinol based on _HLA-B_ genotype\r\n\r\n| Likely Phenotype | Genotypes | Examples of diplotypes | Implications for phenotypic measures   | Recommendations for allopurinol therapy | Classification of recommendation for allopurinol therapy |\r\n| --- | --- | --- | --- | --- | --- |\r\n| Low or reduced risk of allopurinol SCAR | Absence of _*58:01_ alleles (reported as \"negative\" on a genotyping test)| *X/*X ^a^|  Low or reduced risk of allopurinol SCAR  |  Use allopurinol per standard dosing guidelines |  Strong |\r\n|Significantly increased risk of allopurinol SCAR | Presence of at least one _*58:01_ allele (reported as \"positive\" on a genotyping test) | _*58:01_/*X ^a^ _*58:01/*58:01_ | Significantly increased risk of allopurinol SCAR| Allopurinol is contraindicated |  Strong |\r\n\r\n_Adapted from Table 2 of the 2013 Guideline Manuscript_\r\n\r\n^a^ *X = any _HLA-B_ genotype other than _*58:01_.\r\n\r\n_HLA-B_ = human leukocyte antigen B",
      "pmids" : [ ],
      "relatedObjects" : [ ],
      "version" : 7
    },
    "version" : 27,
    "xrefs" : [ {"@id":"https://api.pharmgkb.org/data/crossReference/url/https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/","@context":"https://www.pharmgkb.org/jsonld/crossReference.jsonld","id":1447983440,"resource":"Web Resource","sameAs":"https%3A%2F%2Fcpicpgx.org%2Fguidelines%2Fguideline-for-allopurinol-and-hla-b%2F","xrefId":"https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"} ]
  },
  "annotationGroups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128786",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128786",
    "name" : "Absent ",
    "annotations" : [ {
      "id" : 1445583358,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986428,
        "externalLinks" : [ ],
        "html" : "<p>Low or reduced risk of allopurinol-induced SCAR</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Low or reduced risk of allopurinol-induced SCAR",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445583357,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986427,
        "externalLinks" : [ ],
        "html" : "<p>Low or reduced risk of allopurinol SCAR (absence of *58:01 alleles (reported as &quot;negative&quot; on a genotyping test))</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Low or reduced risk of allopurinol SCAR (absence of *58:01 alleles (reported as \"negative\" on a genotyping test))",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445583359,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986429,
        "externalLinks" : [ ],
        "html" : "<p>Use allopurinol per standard dosing guidelines.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Use allopurinol per standard dosing guidelines.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 6
    } ],
    "genePhenotypes" : [ "HLA-B:Absence/Absence" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166105003",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166105003",
      "name" : "CPIC Guideline for allopurinol and HLA-B",
      "version" : 27
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 6
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://api.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128787",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128787",
    "name" : "Present",
    "annotations" : [ {
      "id" : 1445583361,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986431,
        "externalLinks" : [ ],
        "html" : "<p>Significantly increased risk of allopurinol-induced SCAR</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Significantly increased risk of allopurinol-induced SCAR",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "resource" : "Guideline Tags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445583360,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986430,
        "externalLinks" : [ ],
        "html" : "<p>Significantly increased risk of allopurinol SCAR (presence of at least one *58:01 allele (reported as &quot;positive&quot; on a genotyping test))</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Significantly increased risk of allopurinol SCAR (presence of at least one *58:01 allele (reported as \"positive\" on a genotyping test))",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "resource" : "Guideline Tags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927",
        "version" : 0
      },
      "version" : 6
    }, {
      "id" : 1445583362,
      "history" : [ ],
      "markdown" : {
        "id" : 1447986432,
        "externalLinks" : [ ],
        "html" : "<p>Allopurinol is contraindicated.</p>\n",
        "internalLinks" : [ ],
        "markdown" : "Allopurinol is contraindicated.",
        "pmids" : [ ],
        "relatedObjects" : [ ],
        "version" : 0
      },
      "type" : {
        "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "resource" : "Guideline Tags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928",
        "version" : 0
      },
      "version" : 6
    } ],
    "genePhenotypes" : [ "HLA-B:Absence/Presence", "HLA-B:Presence/Presence" ],
    "guideline" : {
      "objCls" : "Guideline",
      "@id" : "https://api.pharmgkb.org/data/guideline/PA166105003",
      "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
      "id" : "PA166105003",
      "name" : "CPIC Guideline for allopurinol and HLA-B",
      "version" : 27
    },
    "rxChangeStatus" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/rxChange/rxChange:1448602495",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 1448602495,
      "resource" : "Prescribing Change",
      "term" : "No",
      "termId" : "rxChange:1448602495",
      "version" : 0
    },
    "strength" : {
      "@id" : "https://api.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "resource" : "Guideline Strength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930",
      "version" : 0
    },
    "version" : 6
  } ],
  "genePhenotypes" : {
    "HLA-B" : {
      "*58:01" : "Presence",
      "Other" : "Absence"
    }
  },
  "citations" : [ {
    "@id" : "https://api.pharmgkb.org/data/literature/26094938",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 15090607,
    "resourceId" : "26094938",
    "title" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update",
    "authors" : [ "Saito Y", "Stamp L K", "Caudle K E", "Hershfield M S", "McDonagh E M", "Callaghan J T", "Tassaneeyakul W", "Mushiroda T", "Kamatani N", "Goldspiel B R", "Phillips E J", "Klein T E", "Lee Mtm" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 6,
    "nonHuman" : false,
    "pubDate" : "2015-06-01T00:00:00-07:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/26094938",
    "sentences" : [ {
      "location" : "title",
      "id" : 15090608,
      "text" : "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update",
      "sentenceIndex" : 0
    }, {
      "location" : "abstract",
      "id" : 15090609,
      "text" : "The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013.",
      "sentenceIndex" : 1
    }, {
      "location" : "abstract",
      "id" : 15090610,
      "text" : "We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current.",
      "sentenceIndex" : 2
    }, {
      "location" : "abstract",
      "id" : 15090611,
      "text" : "However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record.",
      "sentenceIndex" : 3
    }, {
      "location" : "abstract",
      "id" : 15090612,
      "text" : "Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).",
      "sentenceIndex" : 4
    } ],
    "summary" : "The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).",
    "type" : "article",
    "version" : 1,
    "year" : 2015
  }, {
    "@id" : "https://api.pharmgkb.org/data/literature/23232549",
    "@context" : "https://api.pharmgkb.org/data/literature.jsonld",
    "id" : 15033427,
    "resourceId" : "23232549",
    "title" : "Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing",
    "authors" : [ "Hershfield M S", "Callaghan J T", "Tassaneeyakul W", "Mushiroda T", "Thorn C F", "Klein T E", "Lee M T M" ],
    "hasKeyword" : true,
    "journal" : "Clinical pharmacology and therapeutics",
    "meshDiseases" : [ ],
    "meshTerms" : [ ],
    "month" : 10,
    "nonHuman" : false,
    "pubDate" : "2012-10-01T00:00:00-07:00",
    "sameAs" : "https://www.ncbi.nlm.nih.gov/pubmed/23232549",
    "sentences" : [ {
      "location" : "title",
      "id" : 15033428,
      "text" : "Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing",
      "sentenceIndex" : 0
    } ],
    "type" : "article",
    "version" : 1,
    "year" : 2012
  } ]
}